Group 1 - The core point of the news is that a block trade of YingTai Bio (stock code: 920819) occurred on November 4, with a transaction volume of 200,000 shares and a transaction amount of 840,000 yuan, at a price of 4.20 yuan, which is a 2.10% discount compared to the closing price of the day [2][3] - In the past month, there have been a total of 9 block trades for this stock, with a cumulative transaction amount of 6.5876 million yuan [3] - The closing price of YingTai Bio on the day of the report was 4.29 yuan, reflecting a decrease of 2.94%, with a daily turnover rate of 1.14% and a total transaction amount of 59.4166 million yuan [3] Group 2 - YingTai Bio was established on July 1, 2005, with a registered capital of 1.2258 billion yuan [3] - The buyer and seller of the block trade were both from CITIC Securities Co., Ltd., Beijing Anwai Dajie Securities Branch [2]

证券代码：920819 证券简称：颖泰生物 公告编号：2025-088 北京颖泰嘉和生物科技股份有限公司 2025 年三季度业绩说明会预告公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、 说明会类型 北京颖泰嘉和生物科技股份有限公司（以下简称"公司"）于 2025 年 10 月 24 日 在 北 京 证 券 交 易 所 指 定 信 息 披 露 平 台（http://www.bse.cn/）发布了《北京颖泰嘉和生物科技股份 有限公司 2025 年三季度报告》（公告编号：2025-078），为方便广大 投资者更深入了解公司 2025 年三季度经营业绩的具体情况，加强 与投资者的互动交流，公司拟召开 2025 年三季度业绩说明会。 二、 说明会召开的时间、地点 （一）会议召开时间：2025 年 11 月 7 日（星期五）15:00-17:00 （二）会议召开地点 公司总经理、董秘：刘晓亮先生 公司财务负责人： 杨玉松先生 四、 投资者参加方式 本次说明会采用网络方式召开。 为充分尊重投资者、提升交流 ...

Core Viewpoint - On November 3, 2023, YingTai Bio (920819) experienced two block trades totaling 533,600 shares and a transaction amount of 1.8441 million yuan, with both trades executed at a discount relative to the closing price [2] Group 1: Trading Activity - The total transaction amount for the two block trades on November 3 was 1.8441 million yuan, with a total volume of 533,600 shares [2] - In the past month, YingTai Bio has recorded a total of 8 block trades, amounting to 5.7476 million yuan [2] - The closing price of YingTai Bio on November 3 was 4.42 yuan, reflecting a 3.03% increase, with a trading turnover rate of 1.66% and a total transaction value of 87.5161 million yuan [2] Group 2: Company Background - Beijing YingTai Jiahe Biotechnology Co., Ltd. was established on July 1, 2005, with a registered capital of 1.2258 billion yuan [2]

Core Viewpoint - YingTai Bio is a leading company in the domestic pesticide industry, focusing on the research, production, and sales of pesticide active ingredients and formulations, with a strong market presence and first-mover advantage in overseas market registrations [1] Group 1: Business Performance - In Q3 2025, YingTai Bio achieved a revenue of 4.434 billion yuan, ranking 9th in the industry, surpassing the industry average of 3.784 billion yuan and the median of 2.036 billion yuan, but significantly behind the top competitors [2] - The net profit for the same period was -11.6313 million yuan, ranking 26th in the industry, well below the industry average of 171 million yuan and the median of 95.2356 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, YingTai Bio's debt-to-asset ratio was 56.10%, slightly down from 56.45% year-on-year, but still above the industry average of 46.06%, indicating relatively high debt pressure [3] - The gross profit margin for Q3 2025 was 12.38%, an increase from 11.44% year-on-year, but still below the industry average of 21.70%, suggesting a need for improved profitability [3] Group 3: Management Compensation - The chairman, Chen Boyang, received a salary of 1.3463 million yuan in 2024, a decrease of 288,700 yuan from 2023 [4] - The general manager, Liu Xiaoliang, earned 729,000 yuan in 2024, down 165,000 yuan from the previous year [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 5.74% to 23,600, while the average number of shares held per shareholder increased by 6.09% to 51,300 [5] - The company is expected to benefit from a partial recovery in the agricultural chemical industry, leveraging its market channels and first-mover advantages [5] Group 5: Future Outlook - Analysts project YingTai Bio's net profit for 2025 to be 42 million yuan, increasing to 153 million yuan in 2026 and 268 million yuan in 2027, maintaining a "buy" rating [5] - Another analysis indicates a reduction in profit forecasts for 2025 to 23 million yuan, 181 million yuan in 2026, and 322 million yuan in 2027, also maintaining a "buy" rating [6]

Core Viewpoint - On October 30, 2023, YingTai Bio (920819) experienced two block trades totaling 414,600 shares and a transaction amount of 1.3858 million yuan, with both trades executed at a discount relative to the closing price [2] Group 1: Trading Activity - The total transaction amount for the two block trades on October 30 was 1.3858 million yuan, with a total volume of 414,600 shares [2] - In the past month, YingTai Bio has recorded six block trades, accumulating a total transaction amount of 3.9034 million yuan [2] - The closing price of YingTai Bio on October 30 was 4.24 yuan, reflecting a decrease of 3.20%, with a daily turnover rate of 1.78% and a total transaction value of 92.9931 million yuan [2] Group 2: Company Background - Beijing YingTai Jiahe Biotechnology Co., Ltd. was established on July 1, 2005, with a registered capital of 1.2258 billion yuan [2]

证券代码：920819 证券简称：颖泰生物 公告编号：2025-087 北京颖泰嘉和生物科技股份有限公司 关于全资子公司涉及诉讼进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 （一）诉讼当事人情况 上市公司子公司所处的当事人地位：被告 1. 上诉人基本信息 名称：龙口市泰和国际贸易有限公司（一审原告） 法定代表人：曲思辉 一、本次重大诉讼事项的基本情况 案件所处的诉讼阶段：二审阶段 收到应诉通知书的日期：2025 年 10 月 27 日 诉讼受理日期：2025 年 10 月 27 日 受理法院的名称：山东省烟台市中级人民法院 二、本次重大诉讼事项的当事人及案件信息 诉讼代理人及所属律所：暂无、暂无 诉讼代理人及所属律所：李思川律师、闫小雨律师、北京市康达 律师事务所 （二）纠纷起因及基本案情 2024 年 7 月，龙口市泰和国际贸易有限公司（以下简称"泰和 贸易"）即本案原告就与公司全资子公司山东福尔有限公司（以下简 称"山东福尔"）即本案被告二及烟台忠慧国际贸易有限公司（以下 简称"烟台忠慧 ...

Core Viewpoint - On October 28, 2023, YingTai Bio (920819) experienced two block trades totaling 405,200 shares and a transaction amount of 1.3123 million yuan, with one trade at a discount rate of up to 28.99% compared to the closing price [2] Trading Summary - The total transaction amount for the two block trades was 1.3123 million yuan, with one trade executed at a discount of 28.99% and another at a premium of 0.24% [2] - In the past month, YingTai Bio has recorded four block trades with a cumulative transaction amount of 2.5176 million yuan [2] Stock Performance - The closing price of YingTai Bio on October 28 was 4.14 yuan, reflecting a decline of 1.19%, with a trading volume of 31.0124 million yuan and a turnover rate of 0.62% [2] - Over the last five days, the stock has seen a cumulative decline of 2.36% [2] Company Background - Beijing YingTai Jiahe Biotechnology Co., Ltd. was established on July 1, 2005, with a registered capital of 1.2258 billion yuan [2]

证券代码：920819 证券简称：颖泰生物 公告编号：2025-081 北京颖泰嘉和生物科技股份有限公司 独立董事提名人声明与承诺 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 提名人北京颖泰嘉和生物科技股份有限公司董事会，现提名潘永 昕先生、翟新利先生、赵旭明先生为北京颖泰嘉和生物科技股份有限 公司第五届董事会独立董事候选人，并已充分了解被提名人职业、学 历、职称、详细的工作经历、全部兼职、有无重大失信等不良记录等 情况。被提名人已书面同意出任北京颖泰嘉和生物科技股份有限公司 第五届董事会独立董事候选人（参见该独立董事候选人声明与承诺）。 提名人认为，被提名人具备独立董事任职资格，与北京颖泰嘉和生物 科技股份有限公司之间不存在任何影响其独立性的关系，且提名人与 被提名人不存在利害关系或者可能妨碍被提名人独立履职的其他关 系，具体声明并承诺如下： 一、被提名人已同时符合以下条件： （一）具备上市公司运作的基本知识，熟悉相关法律法规、部门 规章、规范性文件及北交所业务规则； （二）具有五年以上履行独立董 ...

证券代码：920819 证券简称：颖泰生物 公告编号：2025-080 北京颖泰嘉和生物科技股份有限公司 董事换届公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律 责任。 一、董事换届的基本情况 根据《公司法》及《公司章程》的有关规定，公司董事会于 2025 年 10 月 23 日审议并通过： 提名陈伯阳先生为公司董事，任职期限三年，本次换届尚需提交股东 会审议，自股东会决议通过之日起生效。该人员持有公司股份 80,000 股， 占公司股本的 0.0065%，不是失信联合惩戒对象。 提名张松山先生为公司董事，任职期限三年，本次换届尚需提交股东 会审议，自股东会决议通过之日起生效。该人员持有公司股份 0 股，占公 司股本的 0.0000%，不是失信联合惩戒对象。 提名张海安先生为公司董事，任职期限三年，本次换届尚需提交股东 会审议，自股东会决议通过之日起生效。该人员持有公司股份 100,000 股， 占公司股本的 0.0082%，不是失信联合惩戒对象。 提名周曙光先生为公司董事，任职期限三年，本次换届尚需提交 ...

证券代码：920819 证券简称：颖泰生物 公告编号：2025-083 北京颖泰嘉和生物科技股份有限公司 独立董事候选人声明与承诺（翟新利） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 本人翟新利，已充分了解并同意由提名人北京颖泰嘉和生物科技 股份有限公司董事会提名为北京颖泰嘉和生物科技股份有限公司第 五届董事会独立董事候选人。本人公开声明，本人具备独立董事任职 资格，保证不存在任何影响本人担任北京颖泰嘉和生物科技股份有限 公司独立董事独立性的关系，具体声明并承诺如下： 一、本人已同时符合以下条件： （一）具备上市公司运作的基本知识，熟悉相关法律法规、部门 规章、规范性文件及北交所业务规则； （二）具有五年以上履行独立董事职责所必需的法律、会计或者 经济等工作经验； （三）具有良好的个人品德，不存在重大失信等不良记录； （四）北交所规定的其他条件。 二、本人任职资格符合下列法律法规、部门规章和规范性文件及 北交所业务规则的要求： （一）《公司法》关于董事任职资格的规定； （二）《中华人民共和国公务员 ...